LivingStone International University

Nurses promote quality services for the betterment of patients when successfully supervised by an effective nurse manager. A nurse managers effectiveness does not only rely on their skill set but their ability to recognise their emotions and that of others and considering how their emotions manifest at the working environment which is a significant requirement  for a nurse manager to leading subordinates and meeting deadlines and achieving set targets. This survey aimed at exploring the determinants and manifestations of nurse manager’s emotional intelligence at health care institutions in Ghana. This was a qualitative study that employed an explorative cross-sectional design and a purposive sampling technique to recruit 15 nurse managers with the assistance of an interview guide. Data collected were manually transcribed using Microsoft word and content analysis conducted. Labels were assigned to significant information generated form transcribed data and emergencing codes identified. Similar codes were combined to form sub-themes and several sub-themes into themes. In all six-sub-themes and three themes were developed form the data. Findings revealed nurse managers' ability to apply emotions (intra-personnel emotional awareness) to handle work-related challenges. Their ability to be emotionally aware of the structures of an organisation enabled them to adapt to a specific leadership style. Additionally, their interpersonal emotional awareness enabled them to socially interact with staff and patients, enabling them to professionally respond to ethical dilemmatic circumstances. The study concluded that, nurse managers were abrased with how their emotional intelligence manifest whilst in active services, therefore health policy makers, stakeholders and nursing professional associations should incorporate emotional intelligence into nursing education and performance review.

Human umbilical cord mesenchymal stem cells (hUC-MSCs) support revascularization, inhibition of inflammation, regulation of apoptosis, and promotion of the release of beneficial factors. Thus, they are regarded as a promising candidate for the treatment of intractable spinal cord injury (SCI). Clinical studies on patients with early chronic SCI (from 2 months to 1 year post-injury), which is clinically common, are rare; therefore, we will conduct a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial at the Third Affiliated Hospital of Sun Yat-sen University, West China Hospital of Sichuan University, and Shanghai East Hospital, Tongji University School of Medicine, China. The trial plans to recruit 66 early chronic SCI patients. Eligible patients will undergo randomization at a 2:1 ratio to two arms: the observation group and the control group. Subjects in the observation group will receive four intrathecal transplantations of stem cells, with a dosage of 1 × 106/kg, at one calendar month intervals. Subjects in the control group will receive intrathecal administrations of 10 mL sterile normal saline in place of the stem cell transplantations. Clinical safety will be assessed by the analysis of adverse events and laboratory tests. The American Spinal Injury Association (ASIA) total score will be the primary efficacy endpoint, and the secondary efficacy outcomes will be the following: ASIA impairment scale, International Association of Neural Restoration-Spinal Cord Injury Functional Rating Scale, muscle tension, electromyogram, cortical motor and cortical sensory evoked potentials, residual urine volume, magnetic resonance imaging-diffusion tensor imaging, T cell subtypes in serum, neurotrophic factors and inflammatory factors in both serum and cerebrospinal fluid. All evaluations will be performed at 1, 3, 6, and 12 months following the final intrathecal administration. During the entire study procedure, all adverse events will be reported as soon as they are noted. This trial is designed to evaluate the clinical safety and efficacy of subarachnoid transplantation of hUC-MSCs to treat early chronic SCI. Moreover, it will establish whether cytotherapy can ameliorate local hostile microenvironments, promote tracking fiber regeneration, and strengthen spinal conduction ability, thus improving overall motor, sensory, and micturition/defecation function in patients with early chronic SCI. This study was approved by the Stem Cell Research Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University, China (approval No. [2018]-02) on March 30, 2018, and was registered with ClinicalTrials.gov (registration No. NCT03521323) on April 12, 2018. The revised trial protocol (protocol version 4.0) was approved by the Stem Cell Research Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University, China (approval No. [2019]-10) on February 25, 2019, and released on ClinicalTrials.gov on April 29, 2019.

Ritorniamo sul volume in oggetto, già schedato da Mario Richter nella sezione «Ottocento. 1850-1900» del numero 188 di “Studi Francesi” per soffermarci maggiormente sui contributi relativi alla prima metà del xix secolo, seguendo la periodizzazione della presente sezione. Come precisato nella Présentation (pp. 7-8) delle curatrici, il volume in oggetto riunisce sei contributi che prendono in considerazione una tipologia testuale – cioè scritti divulgativi, “guide” di Parigi che talvolta non s...

Introduction: Ischemic stroke (IS) is a medical emergency with a high risk of morbidity, leading to disability, and mortality. IS’s impact on our patients’ lives and healthcare system make it essential to optimize its immediate management, triage requirements, and plans for transfer to comprehensive stroke centers. In this study, we hypothesized that it is possible to predict the mortality of IS patients within the first hour of hospital admission. Methods: With the approval of the Human Studies Committee (IRB #: 13.0396), we performed a retrospective analysis from the Stroke Quality Database. Patients who were admitted between 2007-2012 were included. In-hospital mortality was the main outcome of the study. Patients’ demographics, baseline illnesses, home medications, baseline neurological assessment scores, and basic laboratory values on admission were included in the analysis as potential factors. Multivariate analysis was performed to assess the independent contributing factors. Data is presented as odds ratio and 95% confidence intervals. Results: IS in-hospital mortality was about 10% in our study population. Multivariate analysis was performed in 2,131 patients. NIH Stroke Scale on admission, recurrent stroke, high WBC levels (>11K), elderly age, AHA Stage II hypertension, baseline use of Ca-channel blockers, and beta-blockers, admission glucose levels and albumin levels independently contributed to in-hospital mortality (Table). Conclusions: IS patients’ baseline characteristics, hospital admission assessment scales, and laboratory values on admission contributed to prediction of in-hospital mortality. Therefore, it is essential to rapidly initiate acute care for high-risk and complex stroke patients. Additionally, focusing on the modifiable factors such as blood pressure management, treating acute infections, and managing glucose levels may help to decrease acute IS mortality.